Dimerix

Dimerix FCF Growth

The Year-over-Year Free Cash Flow Growth of Dimerix (DXB.AX) as of Oct 11, 2026 is -232.75 %. In the previous year, Year-over-Year Free Cash Flow Growth was 656.02 % — a change of -135.48% (lower).

FCF Growth

-232.75 %

YoY

-135.48%

Last updated:

Year-over-Year Free Cash Flow Growth of Dimerix is 2026 -232.75 % . Year-over-Year Free Cash Flow Growth of Dimerix was 2025 656.02 % . It decreases by -135.48% lower compared to the previous year.

The Dimerix FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
14.59 AUD
Jan 1, 2020
-71.56 AUD
Jan 1, 2021
-36.81 AUD
Jan 1, 2022
-107.75 AUD
Jan 1, 2023
5.31 AUD
Jan 1, 2024
44.87 AUD
Jan 1, 2025
656.02 AUD
Jan 1, 2026
-232.75 AUD
The Dimerix FCF Growth history
YEARFCF GrowthYoY
-232.75 %-135.48%
656.02 %+1,362.10%
44.87 %+745.29%
5.31 %-104.93%
-107.75 %+192.76%
-36.81 %-48.56%
-71.56 %-590.29%
14.59 %-120.01%
-72.95 %+107.37%
-35.18 %-75.69%
-144.69 %+20,706.59%
-0.70 %—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Year-over-Year Free Cash Flow Growth of Dimerix is -232.75 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Dimerix since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Dimerix historically and in real time.

Access this data via the Eulerpool API

Growth — Dimerix

All Key Metrics — Dimerix